ALVR Allovir Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALVR

Price (delayed)

$4.21

Market cap

$393.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$321.92M

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative ...

Highlights
ALVR's EPS is up by 21% QoQ and by 20% YoY
The net income is up by 11% since the previous quarter
The quick ratio is up by 47% year-on-year but it has declined by 25% since the previous quarter
Allovir's debt has soared by 63% from the previous quarter and by 18% YoY
The equity has declined by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allovir.com
Peers: OVID

Key stats

What are the main financial stats of ALVR
Market
Shares outstanding
93.46M
Market cap
$393.48M
Enterprise value
$321.92M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$168.98M
EBITDA
-$166.41M
Free cash flow
-$142.05M
Per share
EPS
-$2.2
Free cash flow per share
-$1.85
Book value per share
$2.41
Revenue per share
$0
TBVPS
$3.61
Balance sheet
Total assets
$277.08M
Total liabilities
$52.56M
Debt
$35.39M
Equity
$224.52M
Working capital
$218.71M
Liquidity
Debt to equity
0.16
Current ratio
9.99
Quick ratio
9.64
Net debt/EBITDA
0.43
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-67.4%
Return on equity
-81.5%
Return on invested capital
-110%
Return on capital employed
-66.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALVR stock price

How has the Allovir stock price performed over time
Intraday
3.19%
1 week
-7.47%
1 month
-36.98%
1 year
-44.39%
YTD
-17.93%
QTD
-17.93%

Financial performance

How have Allovir's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$171.2M
Net income
-$168.71M
Gross margin
N/A
Net margin
N/A
The net income is up by 11% since the previous quarter
The operating income has grown by 8% from the previous quarter

Growth

What is Allovir's growth rate over time

Valuation

What is Allovir stock price valuation
P/E
N/A
P/B
1.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALVR's EPS is up by 21% QoQ and by 20% YoY
The price to book (P/B) is 20% less than the last 4 quarters average of 2.2
The equity has declined by 11% since the previous quarter

Efficiency

How efficient is Allovir business performance
ALVR's return on equity is down by 33% year-on-year but it is up by 10% since the previous quarter
Allovir's return on invested capital has increased by 32% YoY and by 25% QoQ
The return on assets has declined by 26% year-on-year but it rose by 10% since the previous quarter

Dividends

What is ALVR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALVR.

Financial health

How did Allovir financials performed over time
The current ratio has grown by 49% YoY but it has contracted by 24% from the previous quarter
The quick ratio is up by 47% year-on-year but it has declined by 25% since the previous quarter
Allovir's debt is 84% less than its equity
ALVR's debt to equity has soared by 78% since the previous quarter and by 23% year-on-year
Allovir's debt has soared by 63% from the previous quarter and by 18% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.